Log in

NASDAQ:ASNDAscendis Pharma A/S Stock Price, Forecast & News

$151.00
-1.85 (-1.21 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$148.70
Now: $151.00
$154.98
50-Day Range
$134.96
MA: $144.88
$156.01
52-Week Range
$90.06
Now: $151.00
$158.93
Volume117,113 shs
Average Volume208,311 shs
Market Capitalization$7.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.98
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Read More
Ascendis Pharma A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.98 million
Book Value$15.87 per share

Profitability

Net Income$-244,180,000.00
Net Margins-2,231.94%

Miscellaneous

Employees216
Market Cap$7.25 billion
Next Earnings Date8/26/2020 (Estimated)
OptionableOptionable

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

How has Ascendis Pharma A/S's stock been impacted by COVID-19 (Coronavirus)?

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ASND shares have increased by 27.4% and is now trading at $151.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ascendis Pharma A/S?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ascendis Pharma A/S.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for Ascendis Pharma A/S.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Tuesday, May, 19th. The biotechnology company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.11. The biotechnology company had revenue of $2.45 million for the quarter, compared to analysts' expectations of $2.66 million. Ascendis Pharma A/S had a negative net margin of 2,231.94% and a negative return on equity of 36.56%. View Ascendis Pharma A/S's earnings history.

What price target have analysts set for ASND?

11 brokers have issued 1 year price objectives for Ascendis Pharma A/S's shares. Their forecasts range from $145.00 to $208.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $172.27 in the next year. This suggests a possible upside of 14.1% from the stock's current price. View analysts' price targets for Ascendis Pharma A/S.

Has Ascendis Pharma A/S been receiving favorable news coverage?

Media coverage about ASND stock has trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Ascendis Pharma A/S.

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the following people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)
  • Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%).

Which institutional investors are buying Ascendis Pharma A/S stock?

ASND stock was acquired by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $151.00.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $7.25 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.